Daily Stormer The Most Censored Publication in History
Adrian Sol
Daily Stormer
April 13, 2018
Miss me yet?
With the only ethical businessman in the pharmaceutical industry, Martin Shkreli, jailed by the Feds, the rats are free to stoop to the lowest ignominies.
It’s a common trope by this point that these medical companies don’t make any money by “curing” diseases, but rather by creating life-long “treatments.”
Well, with a potential “cure-all” on its way, gene therapy, it’s not surprising that these bastards are starting to scheme ways to keep the stupid goyim paying for their pills forever.
CNBC:
Goldman Sachs analysts attempted to address a touchy subject for biotech companies, especially those involved in the pioneering “gene therapy” treatment: cures could be bad for business in the long run.
Imagine being such as piece of garbage that you’d utter those words.
“It’s just business, goyim. A man’s gotta earn his shekels, after all.”
Obviously, it’s an open secret that these companies favor research into long term expensive treatments rather than one-shot cures. But to actually go out there and say it publicly… Wow.
“Is curing patients a sustainable business model?” analysts ask in an April 10 report entitled “The Genome Revolution.”
“The potential to deliver ‘one shot cures’ is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies,” analyst Salveen Richter wrote in the note to clients Tuesday. “While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.”
Sorry, kid, but curing you would challenge our sustained cash flow.
This Goldman Sachs dude isn’t even a Jew, too; he’s some kind of pajeet, from what I’ve found out. While a Jew would have the same ideas, he wouldn’t be so stupid and autistic as to express them so bluntly like that. He would have used language coded with complexity to the point that mainstream normie publications couldn’t report on it.
Out of the mouth of pajeets, as they say.
Richter cited Gilead Sciences’ treatments for hepatitis C, which achieved cure rates of more than 90 percent. The company’s U.S. sales for these hepatitis C treatments peaked at $12.5 billion in 2015, but have been falling ever since. Goldman estimates the U.S. sales for these treatments will be less than $4 billion this year, according to a table in the report.
Yeah, can’t have that, can we?
In time, gene therapy could be used to permanently cure a vast array of diseases and disabilities. In time, with even more advanced technology, these genetic defects could even be weeded out of the gene pool entirely, without even needing any eugenic policies.
The Goldman Sachs guy says his “solution” is to nickle and dime people for each little problem separately (“constant innovation and portfolio expansion”). The problem is that this is a pretty artificial way to do things.
Gene therapy works by infecting someone with a virus which will “edit” new genes into their cells.
Obviously, viruses are self replicating. You don’t need regular treatments. Moreover, there’s no real reason why a single treatment couldn’t change every single gene that causes problems. A single injection could cure your eye problems, your susceptibility to heart failure, give you immunity to various diseases, prevent osteoporosis, and so on.
A machine could be given your DNA sample, analyze it, and put together the package of genes the virus needs to edit. This would then be injected and you’d be cured of all your genetic problems for good.
So I don’t know what he’s actually suggesting here. But the basic message is clear: gene therapy (and by extension all permanent cures) are bad for business.
This is why we need to get these Jews and their pajeet underlings out of our country.
